ClinicalTrials.gg
RecruitingNCT07332455Updated Nov 9, 2026

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

A Phase 1/2 interventional study of GSK5471713 in Neoplasms, Prostate, sponsored by GlaxoSmithKline. Recruiting at 20 sites in 8 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 28, 2026Eligibility revised5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies in Prostatic Neoplasms by GlaxoSmithKline — 3 open to participants now, 3 under way, 1 of them phase 3. Prostatic Neoplasms · GlaxoSmithKline.

Planned enrollment
9th of 13
54 · median 113
Started
2026
with 1 other
Phase 1/2
2 of 17
2 open now
Registered
16th of 17
by date

Among the 17 studies in Prostatic Neoplasms by GlaxoSmithKline, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1/2, and was the 16th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 17 studies in Prostatic Neoplasms by GlaxoSmithKline are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Prostatic Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.

03

Conditions studied

  • Neoplasms, Prostate

Browse trials for

Keywords

  • Metastatic castration-resistant prostate cancer
  • First-Time-in-Human
  • GSK5471713
  • Prostate cancer
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with mCRPC that have or cytologically confirmed adenocarcinoma of the prostate.
  • Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).
  • (ECOG) performance status (PS) 0 or 1 and of ≥3 months (≥12 weeks).
  • Progression on ADT and >=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane-based chemotherapy regimens. Participants should have received all approved standard-of-care therapies for which they are eligible, including biomarker directed therapy, in accordance with current clinical guidelines, unless a documented or another justified medical reason precluded their use.

Exclusion criteria

Exclusion Criteria:

  • Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.
  • Impaired cardiac function or cardiac disease.
  • Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.
  • Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Participants receiving GSK5471713

    Participants will receive GSK5471713, according to their allocated dose level guided by the dose escalation study design.

    Drug: GSK5471713

Interventions

  • DrugGSK5471713

    GSK5471713 will be administered at different dose levels based on the dose escalation study design

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs)

    Time frame: 28 days

  2. Number of participants with adverse events (AEs), and serious adverse events (SAEs)

    Time frame: Approximately 45 months

  3. Number of participants with adverse events (AEs), and serious adverse events (SAEs) by Severity

    Time frame: Approximately 45 months

  4. Number of participants with AEs leading to dose modifications

    Time frame: Approximately 45 months

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of GSK5471713

    Time frame: Approximately 45 months

  2. Area under the plasma concentration-time curve from 0 to t (AUC[0-t]) of GSK5471713

    Time frame: Approximately 45 months

  3. Time to maximum plasma concentration (Tmax) of GSK5471713

    Time frame: Approximately 45 months

  4. Prostate-specific Antigen Decrease from Baseline >=50% (PSA50) Response Rate

    PSA50 response is defined as a greater than or equal to (\>=)50 percent (%) decline in PSA from Baseline, confirmed at least 3 weeks later.

    Time frame: Approximately 45 months

  5. Objective response rate (ORR) per Prostate Cancer Working Group 3 (PCWG3) by investigator assessment

    ORR is defined as the percentage of participants in the ORR Evaluable set who have the Best overall response (BOR) of confirmed Complete response (CR) or Partial response (PR) per PCWG3 guidelines as assessed by investigator.

    Time frame: Approximately 45 months

07

Study locations

20 of 20 sites recruiting
  • GSK Investigational Site
    La Jolla, California 92093-1503, United States
    Recruiting
  • GSK Investigational Site
    Los Angeles, California 90095, United States
    Recruiting
  • GSK Investigational Site
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107-4330, United States
    Recruiting
  • GSK Investigational Site
    West Valley City, Utah 84119-3602, United States
    Recruiting
  • GSK Investigational Site
    Melbourne, Victoria 3000, Australia
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H2X 3E4, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • GSK Investigational Site
    Montpellier, 34298, France
    Recruiting
  • GSK Investigational Site
    Villejuif, 94805, France
    Recruiting
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
    Recruiting
  • GSK Investigational Site
    Tokyo, 135-8550, Japan
    Recruiting
  • GSK Investigational Site
    Amsterdam, 1066 CX, Netherlands
    Recruiting
  • GSK Investigational Site
    Nijmegen, 6525 GA, Netherlands
    Recruiting
  • GSK Investigational Site
    Seoul, Seoul Teugbyeolsi 06351, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 120-752, South Korea
    Recruiting
  • GSK Investigational Site
    Logroño, La Rioja 26006, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 08035, Spain
    Recruiting
  • GSK Investigational Site
    Málaga, 29010, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 25 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 12, 2026
StartActual
Feb 10, 2026
Primary completionEst.
Mar 24, 2028
CompletionEst.
Mar 26, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed
Show 5 added (3 Spain, 1 United States, 1 France)
  • GSK Investigational Site · Los Angeles, United States
  • GSK Investigational Site · Villejuif, France
  • GSK Investigational Site · Logroño, Spain
  • GSK Investigational Site · Barcelona, Spain
  • GSK Investigational Site · Málaga, Spain
Show 1 removed
  • GSK Investigational Site · Logroño, Spain
Oct 28, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedEastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 and life expectancy of ≥3 months (≥12 weeks).
  • EditedProgression on ADT and >=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane -based chemotherapy regimens. Participants should have received all approved standard-of-care therapies for which they are eligible, including biomarker directed therapy, in accordance with current clinical guidelines, unless a documented contraindication or another justified medical reason precluded their use.
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • GSK Investigational Site · Seoul, South KoreaContact person changed (no phone or email listed)
Oct 28, 2026
Show all 2 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 28, 2026
    5 sites added, 1 site removed
    Show 5 added (3 Spain, 1 United States, 1 France)
    • GSK Investigational Site · Los Angeles, United States
    • GSK Investigational Site · Villejuif, France
    • GSK Investigational Site · Logroño, Spain
    • GSK Investigational Site · Barcelona, Spain
    • GSK Investigational Site · Málaga, Spain
    Show 1 removed
    • GSK Investigational Site · Logroño, Spain
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedEastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 and life expectancy of ≥3 months (≥12 weeks).
    • EditedProgression on ADT and >=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane -based chemotherapy regimens. Participants should have received all approved standard-of-care therapies for which they are eligible, including biomarker directed therapy, in accordance with current clinical guidelines, unless a documented contraindication or another justified medical reason precluded their use.
    Site contacts Changed at 1 site. See the sites
    Show the site
    • GSK Investigational Site · Seoul, South KoreaContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07332455
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Feb 10, 2026
Primary completion
Mar 24, 2028 (estimated)
Completion
Mar 26, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion